Physician profile
Alan B Fortier
NPI 1760692081
$7,451.03
in general payments reported to CMS, 2019-2025
44 companies · $1,241 in 2025
The $1,241 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $992 · 2020: $540 · 2021: $1,212 · 2022: $1,189 · 2023: $1,225 · 2024: $1,052 · 2025: $1,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,518.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,389.05 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $831.24 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Novo Nordisk INC | $766.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $700.02 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $578.80 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $502.10 | 2019-2025 | |
| Amgen INC. | $344.82 | 2019-2024 | Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $235.84 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Merck Sharp & Dohme LLC | $202.41 | 2019-2025 | Pifeltro, Dificid, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.30 | 2019-2025 | Ofev, Jardiance |
| Janssen Pharmaceuticals, INC | $170.36 | 2019-2022 | |
| Allergan, INC. | $169.38 | 2019-2020 | |
| Astellas Pharma US INC | $153.16 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.57 | 2020-2023 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $88.18 | 2019-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Fortier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.